Universal Ibogaine Inc.
IBO.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -16.35% | 25.07% | 123.76% | 285.05% | 288.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.35% | 25.07% | 123.76% | 285.05% | 288.87% |
| Cost of Revenue | 5.70% | 28.77% | 66.19% | 86.75% | 111.63% |
| Gross Profit | -70.85% | 9.29% | 2,044.02% | 328.37% | 464.14% |
| SG&A Expenses | -26.40% | -34.74% | -41.33% | -53.30% | -65.35% |
| Depreciation & Amortization | 4.30% | 7.48% | 14.55% | 14.48% | 10.17% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.28% | 1.26% | 3.71% | -16.44% | -33.29% |
| Operating Income | -37.02% | 26.91% | 56.55% | 74.30% | 79.87% |
| Income Before Tax | -88.71% | -23.51% | 15.38% | 75.03% | 83.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -88.71% | -23.51% | 15.38% | 75.03% | 83.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.71% | -23.51% | 15.38% | 75.03% | 83.08% |
| EBIT | -37.02% | 26.91% | 56.55% | 74.30% | 79.87% |
| EBITDA | -59.71% | 36.67% | 68.54% | 83.34% | 87.15% |
| EPS Basic | -23.40% | 13.04% | 36.17% | 79.42% | 82.78% |
| Normalized Basic EPS | 17.39% | 47.37% | 62.96% | 77.38% | 77.45% |
| EPS Diluted | -40.43% | 1.45% | 27.66% | 81.41% | 84.28% |
| Normalized Diluted EPS | 17.39% | 47.37% | 62.96% | 77.38% | 77.45% |
| Average Basic Shares Outstanding | 51.91% | 36.73% | 21.65% | 12.47% | 0.41% |
| Average Diluted Shares Outstanding | 51.91% | 36.73% | 21.65% | 12.47% | 0.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |